<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Critical Role Spns2, Sphingosine-1-Phosphate <br /> Transporter, Lung Cancer Cell <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span>Survival</span> Migration <br /> Eric Bradley1, Somsankar Dasgupta1, Xue Jiang2, Xiaying Zhao1, Gu Zhu1, Qian He1, Michael Dinkins1, <br /> Erhard Bieberich1, Guanghu Wang1* <br /> 1 Department Neuroscience Regenerative Medicine, Medical College Georgia, Georgia Regents University, Augusta, Georgia, United States America, <br /> 2 Shengjing Hospital, China Medical University, Shenyang, Liaoning, P.R. China <br />  <br />  <br />  <br />     <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />     The sphingosine-1-phosphate (S1P) transporter Spns2 regulates myocardial precursor migration zebrafish and <br />     lymphocyte trafficking mice. However, function cancer investigated. We ectopic <br />     Spns2 expression induced apoptosis knockdown enhanced cell migration non-small cell lung cancer (NSCLC) cells. <br />     Metabolically, Spns2 expression increased extracellular S1P level knockdown intracellular. Pharmacological <br />     inhibition S1P synthesis abolished augmented cell migration mediated Spns2 knockdown, indicating that <br />     intracellular S1P plays key role process. Cell signaling studies indicated Spns2 expression impaired GSK-3b and <br />     Stat3 mediated pro-survival pathways. Conversely, pathways activated Spns2 knockdown, explains the <br />     increased cell migration crucial migration. Alterations Spns2 affect enzymes <br />     involved S1P metabolism, including sphingosine kinases, S1P phosphatases, S1P lyase 1. Genetically, Spns2 mRNA <br />     level reduced advanced lung cancer (LC) patients quantified using small scale qPCR array. These <br />     data time Spns2 plays key roles regulating cellular functions NSCLC cells, down- <br />     regulation potential risk factor LC. <br />  <br />   Citation: Bradley E, Dasgupta S, Jiang X, Zhao X, Zhu G, et al. (2014) Critical Role Spns2, Sphingosine-1-Phosphate Transporter, Lung Cancer <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-86' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-133' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-137' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span>Cell Survival</span> <br />   Migration. PLoS ONE 9(10): e110119. doi:10.1371/journal.pone.0110119 <br />   Editor: Junming Yue, The University Tennessee Health Science Center, United States America <br />   Received June 17, 2014; Accepted September 8, 2014; Published October 20, 2014 <br />   Copyright: &#195;&#376; 2014 Bradley et al. This open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Data Availability: The authors confirm data underlying findings fully available restriction. All relevant data body and <br />   Supporting Information files paper. <br />   Funding: This project supported Intramural grant Georgia Regents University SDG award American Heart Association (GW). The <br />   funders role study design, data collection analysis, decision publish, preparation manuscript. <br />   Competing Interests: The authors declared competing interests exist. <br />   * Email: gwang@gru.edu <br />  <br />  <br />  <br /> Introduction                                                                              Sphingosine 1-phosphate (S1P) potent bioactive signaling <br />                                                                                        molecule plays vital roles diverse physiological and <br />    Lung cancer (LC) leading cause cancer related death                    pathological processes immunity cancer <br /> the United States worldwide [1,2]. In 2012,                         [10,11,12,13]. It promotes cancer regulating cell prolifera- <br /> than 220,000 new cases 160,000 deaths                             tion/survival, migration, angiogenesis, lymphangiogenesis <br /> United States [1,3,4]. LC remarkably heterogeneous                          [10,14,15]. One enzymes generates S1P, sphingosine <br /> disease. Its major forms non-small cell LC (NSCLC)                         kinase 1 (SphK1) (Fig. 1A), regarded oncogenic enzyme, <br /> small cell LC, NSCLC common form                               activity stimulated wide range agonists, e.g. <br /> which accounts 85% newly diagnosed cases [1,4].                           hormones growth factors [16,17]. Conversely, enzyme <br />    Genetic abnormalities linked multiple genes signaling                      degrades S1P, S1P lyase 1(SGPL1) (Fig. 1A), down- <br /> pathways NSCLC, including epidermal growth factor receptor                          regulated prostate cancer [17]. Silencing SGPL1 enhances <br /> (EGFR) family, signal transducer activator transcription 3                      cell survival; enforced SGPL1 expression sensitizes cell <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br /> (Stat3), phosphoinositide 3-kinase&#226;&#8364;&#8220;Akt&#226;&#8364;&#8220;mTOR pathways                               irradiation chemotherapy [17]. In addition, aspects the <br /> [1,2,4]. These discoveries led uniquely targeted therapies                     S1P signal pathways closely related tumorigenesis (Fig. 1A) <br /> with specific inhibitor drugs erlotinib gefitinib                      [10,18]. Extracellular S1P exerts function five <br /> mutations EGFR [5] crizotinib gene translocation                             cell surface G-protein-coupled-receptors S1P1&#226;&#8364;&#8220;S1P5 [10]. It <br /> resulting EML4-ALK oncogene [6]. Epigenetic variations                          stimulates different signal transduction pathways different cell <br /> are linked NSCLC [7,8]. Although diagnosis                             types, cell, depending receptors <br /> treatment rapidly evolving, meaningful improvements                              expressed. For example, S1P1 coupled exclusively Gi protein <br /> outcomes NSCLC patients elusive [1,3]. Many                         activate Ras, mitogen activated protein kinase (MAPK), PI3K/ <br /> patients relapse form aggressive metastatic tumors [9].                       Akt, phospholipase C pathways [10,19]. The intracellular <br /> Thus deeper understanding origins molecular                           S1P, hand, promotes cancer progression a <br /> mechanisms metastasis disease urgently needed order                    receptor-independent manner [11,12], mediating calci- <br /> to improve prevention treatment.                                                   um release endoplasmic reticulum, interacting its <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                         1                            October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                    Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />  <br /> Figure 1. Ectopic Spns2 expression induced apoptosis A549 cells. (A), Schematic representation S1P metabolism function, <br /> SGPP, S1P phosphatase; SphK, sphingosine kinase; SGPL, S1P lyase; pEA, phosphoethanolamine. (B), Western blot analysis Spns2-EGFP expression <br /> detected anti-GFP antibody. b-actin (Actin) used loading control. A549 cells transfected Spns2-EGFP cell lysates <br /> collected 48 hours later. The molecular weight Spns2-GFP 84 kD (58+26; arrow). (C), Spns2 expression increased extracellular level S1P, <br /> sphingosine (Sph), dihydrosphingosine (dhSph). Cells changed media delipidated FBS 24 hours transfection. Another 24 <br /> hours later, media collected centrifuged, supernatant analyzed lipidomics. (D), Time lapse images Spns2 positive cells. A549 <br /> cells transfected Spns2-EGFP A. 12&#226;&#8364;&#8220;16 hours later, cells placed environmental chamber maintains 37uC 5% CO2 <br /> and time lapse images taken time points indicated. Scale bar 10 mm. (E), Confocal laser scan images cells immuno-stained active (cleaved) <br /> caspase 3 (Casp3). A549 cells transiently transfected, fixed stained antibody cleaved Casp3. Scale bar 20 mm. <br /> doi:10.1371/journal.pone.0110119.g001 <br />  <br />  <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                2                         October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                Role Spns2 Lung Cancer Cells <br />  <br />  <br /> intracellular targets, HDAC TNF receptor-associated              Fisher Scientific, Austin, TX), Pen/Strep (Life Tech.). <br /> factor 2 (TRAF2) [20]. More importantly, S1P elevation              HBEpC maintained according manufacturer&#226;&#8364;&#8482;s instructions. <br /> implicated risk factor LC epidemiological study [21].         Transfection Spns2 siRNAs performed Lipofec- <br />    S1P generated intracellularly SphKs cellular level       tamine 2000 according manufacturer&#226;&#8364;&#8482;s instructions (Life <br /> maintained fine-tuned equilibrium generation,                     Tech.) electroporated using Nucleofactor (Lonza, Allendale, <br /> conversion, degradation, exportation (Fig. 1A). S1P                   NJ). <br /> exported cells transporter proteins (Fig. 1A). Several           Live cell time lapse imaging, immunocytochemistry, and <br /> ATP-binding cassette (ABC) family members, ABCA1,                    confocal laser microscopy. Live cell imaging performed <br /> ABCC1, ABCG1 proposed transport S1P based                   following previous published procedures [35,36,37,38]. Briefly, <br /> on observations knockdown pharmacological                      cells transfected Spns2-GFP. Sixteen hours later, the <br /> inhibition decrease S1P release [22,23,24,25,26]. However,              culture live cell imaging chamber phase contrast <br /> notion remains controversial S1P exportation altered            micrographs taken 30&#226;&#8364;&#8220;60 minutes Nikon Eclipse <br /> when proteins exogenously expressed cells knocked            TE300 (Nikon Instruments, Inc., Melville, NY, USA. For <br /> out mice [18,27,28]. Recently, spinster homolog 2 (Spns2),              immunocytochemistry laser confocal microscopy, fixed <br /> member major facilitator superfamily non-ATP-                      cells immunostained antibodies listed images taken <br /> dependent transporters, shown transport S1P                 using Zeiss LSM510 confocal laser scanning microscope <br /> in vitro vivo [27,29,30,31,32,33,34]. More interestingly,             equipped photon argon laser 488 nm(Cy2), <br /> although reduced plasma, S1P levels increased              543 nm(Cy3), 633 nm(Cy5, Alexa Fluor 647), respectively. <br /> some tissues including lung Spns2 deficient mice [33],           LSM 510 Meta 3.2 software used image acquisition. <br /> consistent previous report showing Spns2 expressed            Adobe Photoshop CS4 used background reduction and <br /> most abundantly human lung [18].                                      editing. Images obtained secondary antibody used <br />    These previous findings prompted hypothesize Spns2             negative controls representing background intensity a <br /> is involved LC development. We performed gain-of-                    particular laser channel. Antigen-specific immunostaining was <br /> function loss-of-function experiments NSCLC cells. We                 quantified counting cells showed signals twofold more <br /> have detected Spns2&#226;&#8364;&#8482;s expression level LC patient samples.           background fluorescence. <br />                                                                                 RNA extraction, RT-PCR, qPCR. RNA extracted <br /> Materials Methods                                                        using TriZol reagent (Invitrogen). First strand cDNA was <br />                                                                              generated iScript cDNA synthesis kit (BioRad, Hercules, <br /> Materials                                                                    CA, USA). Real time qPCR performed using SYBR green/ <br />    Antibodies phospho-GSK-3b (Ser 9), GSK-3b, phos-                  Rox qPCR master mix PTC-200 Gradient Cycler equipped <br /> pho-Stat3, Stat3, cleaved Caspase 3, Survivin Cell             chromo 4 continuous fluorescent detector (BioRad). The <br /> Signaling Technologies (Danvers, MA). Antibodies AIF                 primers qPCR were: human hSpns2 forward: TTA CTG <br /> and b-actin Santa Cruz Biotechnology (Santa Cruz,                  GCT CCA GCG TGA, hSpns2 reverse: TGA TCA TGC CCA <br /> CA). The antibody LC3B Abcam (Cambridge,                    GGA CAG; hPOLR2A forward: GGGTGGCATCAAATACC- <br /> MA). The antibody SphK2 Exalpha Biologicals                 CAGA; hPOLR2A reverse: AGACAC AGCGCAAAACTTTCA; <br /> (Dublin, OH). The fluorescent labeling inhibitors caspases             hSphK1 forward: GGC TGC TGT CAC CCA TGA A, <br /> (FLICA) kit Immunochemical Technologies (Blooming-                  hSphK1reverse: TCA CTC TCT AGG TCC ACA TCA G; <br /> ton, MN). SphK inhibitor Ski-1 Biovision (Milpitas, CA).            hSphK2 forward: AGC GTG GTA GCC ACT TCA G, hSphK2 <br /> The pan caspase inhibitor Z-VAD Promega (Madison,                   reverse: GAG CAG TGT ACC GAT GCC A; hSGPP1 forward: <br /> WI). The PI3K inhibitor LY294002 Cayman (Ann                        ATC ATC ATC GGG CTT CAT TTA GC, hSGPP1reverse: <br /> Arbor, MI). And Jak inhibitor JAKi Millipore                    GTG CTC CAG GTG TCA AGA GT; hSGPP2 forward, TCA <br /> (Billerica, MA). Human LC real time PCR arrays                     C CG CAC TCC TCA TCG T, hSGPP2 reverse: CCG GGT <br /> Origene (Rockville, MD).                                                     TGG GCT GTA GTA ATC; hSGPL1 forward: CCT AGC ACA <br />                                                                              GAC CTT CTG ATG T, hSGPL1 reverse: ACT CCA TGC <br /> Methods                                                                      AAT TAG CTG CCA; hABCA1 forward: TTA AAC GCC CTC <br />                                                                              ACC AAA GAC, hABCA1reverse: AAA AGC CGC CAT ACC <br />    Plasmid cloning. Human SPNS2 PCR amplified                     TAA ACT; hABCC1 forward: TTA CTC ATT CAG CTC GTC <br /> BAC using primers hSpns2forward: AAG CTT ATG TGC CTG                         TTG TC, hABCC1reverse: CAG GGA TTA GGG TCG TGG <br /> GAA TGC GCC TCG, hSPns2reverse: GGT ACC AA GAC                           AT; hABCG1 forward: ACT GCA GCA TCG TGT ACT GGA, <br /> TTT CAC AGA TGC GGG CGG; subcloned                              hABCG1reverse: CGT CTC GTC GAT GTC ACA GTG; <br /> pGEM Teasy vector (Promega, Madison, WI). The fragment                   hABCG2 forward: TGA GCC TAC AAC TGG CTT AGA, <br /> digested using enzymes HindIII KpnI cloned                      hABCG2 reverse: CCC TGC TTA GAC ATC CTT TTC AG. <br /> pEGFP-N1 vector (Clontech, Mountain View, CA), resulting                     Cell viability cell death assays. Proliferation and <br /> the pSPNS2-EGFP construct. For HA tagged Spns2, primers                      apoptosis assays performed A549 H1299 cells <br /> containing HA tag designed. The PCR product                     transfected hSPNS2-EGFP HA-Spns2 previously <br /> cloned pCDNA3.1 (Life Tech., Carlsbad, CA, USA) similar              described [39,40,41]. The number live cells measured by <br /> pSPNS2-EGFP.                                                                 microplate reader using Cell Counting Kit-8 (CCK8) <br />    Cell culture treatment. The human NSCLC cell lines                    (Dojindo Molecular Technologies, Inc, based the <br /> A549 H1299 (ATCC, Manassas, VA) generous gifts                      dehydrogenase activity viable cells). Briefly, CCK8 solution <br /> <span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> Dr. Zhonglin Hao, Cancer Center, Georgia Regents                        added treated cell culture, incubated 2&#226;&#8364;&#8220;4 hours, and <br /> University. The primary human brachial epithelial cells (HBEpC)              absorption wavelength 450 nm read microplate <br /> were ATCC (Manassas, VA). A549 cells H1299 cells                    reader. The absorption 450 nm correlated live cell <br /> were maintained Dulbecco&#226;&#8364;&#8482;s modified Eagle&#226;&#8364;&#8482;s medium (Cellgro,              number present well. The FLICA assay performed with <br /> Herndon, VA, USA) containing 10% FBS (Hyclone, Thermo                        Spns2-EGFP plasmid-transfected A549 cells using sulforhoda- <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               3                       October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                  Role Spns2 Lung Cancer Cells <br />  <br />  <br /> mine-labeled fluoromethyl ketone peptide inhibitor (red) according          Results <br /> to manufacturer&#226;&#8364;&#8482;s instructions. Briefly, 48 hours post- <br /> transfection Spns2-EGFP plasmids, FLICA reagent                Ectopic Spns2 expression induces cell death NSCLC <br /> was added medium cells incubated 1 hour               cells <br /> 37uC 5% CO2. The cells washed washing                     To study Spns2&#226;&#8364;&#8482;s function LC, used NSCLC cells. We first <br /> solution fixed 4% p-formaldehyde phosphate                 attempted establish Spns2-EGFP stable-expressing A549 cell <br /> buffered saline analysis microscopy.                         line, line obtained (data shown). Thus we <br />    Flow cytometry analysis. Spns2-GFP transfected A549 cells                focused transient expression Spns2. Western blot analysis <br /> were collected, fixed 4% paraformaldehyde, immuno-                   using anti-GFP antibody indicated Spns2 expressed as <br /> labeled Caspase 3 antibody followed Alexa Fluor                     ,84 kD fusion protein (58 kD+26 kD; arrow, Fig. 1B). To <br /> 555 secondary antibody. The labeled cells analyzed                ensure ectopic expressed Spns2 functional, we <br /> Becton Dickinson FACSCalibur 4-color analyzers equipped 4              measured transported S1P. Lipidomics data showed <br /> lasers (BD BioSciences, San Jose, CA).                                      S1P level culture medium increased by <br />    Cell migration assays. Cell migration measured                    5.660.55 fold (Fig. 1C), consistent previous reports <br /> wound healing assays previously published [42]. Briefly, cells           [29,31,32,33,34] confirming transfected Spns2 was <br /> were transfected Spns2 siRNAs scrambled control                  fully functional. Interestingly, extracellular levels sphingosine <br /> lipofectamine 2000. Cells grown 72 hours time             (Sph) dihydrosphingosine (dhsph) increased 1.5 <br /> they confluent. A gap 400 mm generated              2.8 fold, respectively (Fig. 1C), implying Spns2 might <br /> by pipette tip. The width gap measured different            transport sphingolipids well. Different species of <br /> time points. For Ski-I treatment, 10 mM Ski-I supplemented              ceramide assayed, showed significant difference <br /> 24 hours siRNA transfection. Cells cultured          compared control (Fig. S1A). <br /> 48 hours assay performed.                                             Next investigated cellular functions Spns2 A549 <br />    Sphingolipid S1P measurement. Cells transfected                      cells. Live cell imaging showed Spns2 cells went through <br /> with Spns2 Spns2 siRNA grown 48 hours                  dramatic morphological changes detached cell <br /> both cell pellets media collected. Cell pellets               culture dishes (arrows Fig. 1D), suggesting apoptotic cell death. <br /> washed times cold PBS. Culture media centrifuged            Thus immuno-labeled cells antibody detecting <br /> for 10 minutes 4uC remove floating cells cell debris. S1P         activated (cleaved) caspase 3 (Casp3) (Fig. 1E). Double-blinded <br /> levels cells culture media measured Lipidomics           quantitative analysis indicates 34.269% Spns2 positive <br /> Core Medical University South Carolina (under                 cells Casp3 positive (Figs. 1E 2A). This induction of <br /> supervision Dr. Jacek Bielawski) according published                  Casp3 confirmed Western blot analysis flow <br />                                                                             cytometry; blocked pan caspase inhibitor Z-VAD <br /> protocols ThermoFisher TSQ Quantum triple quadrupole <br />                                                                             (Figs. 2B, S1B, S1C). Induction Casp3 reproduced by <br /> mass spectrometer, operating Multiple Reaction Monitoring <br />                                                                             expression HA-Spns2 smaller tag (not shown). In <br /> (MRM) positive ionization mode, using modified version [43]. <br />                                                                             line Casp 3 activation, anti-apoptosis gene Survivin was <br /> Briefly, cell pellets media corresponding 2&#226;&#8364;&#8220;36106 cells, <br />                                                                             significantly reduced (Fig. 2B) [36,44]. Apoptosis Inducing factor <br /> were fortified internal standards (ISs: C17 <span id='am-316' about='xsp:base' typeof='owl:Thing'>base</span> D-erythro- <br />                                                                             (AIF) cleaved LC3B measured, were <br /> sphingosine (17CSph), C17 sphingosine-1-phosphate (17CSph-1P), <br />                                                                             increased Spns2 expression (Fig. 2B), suggesting Spns2 <br /> N-palmitoyl-D-erythro-C13 sphingosine (13C16-Cer) hepta- <br />                                                                             does induce caspase-independent apoptosis autophagy. <br /> decanoyl-D-erythro-sphingosine (C17-Cer)), extracted with <br />                                                                                To validate Spns2 induced apoptosis, performed <br /> ethyl acetate/iso-propanol/water (60/30/10 v/v) solvent system. <br />                                                                             FLICA (fluorescent labeled inhibitor pan caspases) assays on <br /> After evaporation reconstitution 100 ml methanol                  living cells. Figure 2C shows typical micrographic images the <br /> samples injected HP1100/TSQ Quantum LC/MS                       assay. Double-blinded quantification demonstrated that <br /> system gradient eluted BDS Hypersil C8,                        70615.9% Spns2 positive cells FLICA positive (Fig. 2D). <br /> 15063.2 mm, 3 mm particle size column, 1.0 mM methano-                    An end result cell death reduction total viable cell <br /> lic ammonium formate/2 mM aqueous ammonium formate                          number. Unbiased cell counting using microplate reader (CCK- <br /> mobile phase system. Peaks corresponding target analytes             8) indicated Spns2 expression resulted 5961.2% reduction <br /> and internal standards collected processed using               viable A549 cells 48 hours (Fig. 2E). These results were <br /> Xcalibur software system. Quantitative analysis based            reproduced NSCLC cell line H1299 (Fig. 2F). <br /> calibration curves generated spiking artificial matrix          Taken together, data demonstrate ectopic Spns2 <br /> known amounts target analyte synthetic standards              expression induces caspase-dependent apoptosis NSCLC cells. <br /> equal internal standards (ISs). The target analyte/IS <br /> peak areas ratios plotted analyte concentration. The <br />                                                                             Spns2 expression modulates S1P metabolism <br /> target analyte/IS peak area ratios samples similarly <br />                                                                                We showed Spns2 expression transported S1P outside of <br /> normalized respective ISs compared calibration <br />                                                                             cells (Fig. 1C). Interestingly, cellular levels S1P, sphingosine, <br /> curves, using linear regression model. Other sphingolipids, such <br />                                                                             different ceramide species significantly altered by <br /> as ceramide sphingosine, assayed.                             Spns2 expression, dhSph long chain ceramide <br />    Statistics. Means standard deviations calculated by <br />                                                                             C20:1were increased 2.0, 1.4 fold, respectively <br /> Microsoft Excel. The statistical significance calculated using          (Fig. 3A shown). <br /> one way ANOVA Tukey&#226;&#8364;&#8482;s post hoc test repeated measure                    To delineate underlying metabolic mechanism, analyzed <br /> ANOVA GraphPad Prism. P,0.05 considered significant.                key enzymes sphingolipid metabolism real time <br />                                                                             quantitative PCR (qPCR). Both SphK1 SphK2 mRNA were <br />                                                                             significantly elevated 24 hours Spns2 transfection, and <br />                                                                             returned normal levels 48 hours (Figs. 3B 3C). Increase <br />                                                                             SphK2 expression confirmed western blot analysis, <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              4                        October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                    Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />  <br /> Figure 2. Ectopic Spns2 expression induces apoptosis NSCLC cells. (A), Quantification Casp3 positive cells shown D. Vehicle (pEGFP) <br /> transfected cells used control (Con). N.100 cells counted separate experiments. (B), Western blot analyses cell death <br /> markers. A549 cells transiently transfected A. Cell lysates collected blotted antibodies indicated. Vehicle (pEGFP) <br /> transfected cells used negative control Actin used loading control. (C), Representative images FLICA staining Spns2 <br /> positive cells. Live A549 cells incubated FLICA 1 hour 48 hours transfection. Cells fixed micrographic images taken. Scale <br /> bar 10 mm. (D), Quantification FLICA positive cells shown C. N.100 cells separate experiments counted double blindly. (E), <br /> Spns2 expression reduced viable cell number A549 cells. Cells transfected A. 48 hours later, relative live cell number measured <br /> by CCK-8 kit using microplate reader. N = 4. (F), Spns2 expression reduced cell number H1299 cells. Live H1299 cell number measured in <br /> I. N = 4. In B, E, H, I, J, error bars represent SD, *, p,0.05, **, p,0.01. <br /> doi:10.1371/journal.pone.0110119.g002 <br />  <br /> except protein level remained relative high level          hours, remained low 48 hours transfection (Figs. 3D <br /> at 48 hours Spns2 transfection (Fig. S1D). This reasonable           S1E). SGPP2 S1P lyase 1 (SGPL1) significantly <br /> since proteins usually longer time degrade mRNA.                 affected Spns2 expression (Figs. S1E&#226;&#8364;&#8220;S1F). These data indicate <br /> S1P phosphatase 1 (SGPP1), enzyme dephosphorylates                   cells alter expression levels multiple key enzymes to <br /> S1P, dramatically reduced 8.5% control level 24              compensate S1P exportation mediated Spns2 expression, <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                5                         October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                  Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />  <br /> Figure 3. Spns2 regulates S1P metabolism S1P receptors. (A), Spns2 expression did alter intracellular level S1P. A549 Cells <br /> were changed media delipidated FBS 24 hours transfection. Another 24 hours later, cells collected, washed lipid levels <br /> analyzed lipidomics. (B), Spns2 expression led acute increase SphK1 A549 cells. Cells transfected, mRNA collected, real time <br /> qRT-PCR performed measure SphK1. (C), Spns2 expression led acute increase SphK2. A549 Cells treated B, qRT-PCR <br /> performed measure SphK2. (D), Spns2 expression led reduction SGPP1 A549 cells. Cells treated B, qRT-PCR <br /> performed measure SGPP1. (E), Spns2 expression reduced S1P receptors. Cells treated B, qRT-PCR performed measure <br /> S1P1, S1P2, S1P3. N = 3. Error bars represent SD. *, p,0.05, **, p,0.01. Data normalized GAPDH. <br /> doi:10.1371/journal.pone.0110119.g003 <br />  <br /> including boosting generation (increase SphKs)                 Akt [35,45]. Figures 4A 4B showed pAkt levels were <br /> halting conversion (reduction SGPP1).                                     reduced Spns2 expression, indicating Spns2 impairs the <br />                                                                              PI3K/Akt pathway. Jak/Stat3 pathway, signal pathway <br /> Spns2 expression leads reduction S1P receptors                     downstream S1P receptors, plays crucial roles cell survival, <br /> multiple pro-survival pathways                                               migration, immune response [46,47]. We determined whether <br />    As mentioned earlier, S1P generally pro-survival factor. To          Spns2 affects pathway measuring Stat3 activity. Western <br /> understand apoptosis induced extracellular S1P              blot analyses showed phospho-Stat3 (pStat3) levels were <br /> was increased Spns2 transfection, detected levels            greatly reduced Spns2 expression cell lines (Figs. 4A <br /> S1P receptors mRNA levels receptors S1P1,              4B). Casp3 activated Spns2 H1299 cells is <br /> S1P2, S1P3 significantly down-regulated Spns2             consistent data obtained A549 cells (Fig. 4B). Next, <br /> expression (Fig. 3E).                                                        immuno-labeled Spns2-EGFP transfected cells antibodies <br />    To confirm observation, determined cell               pGSK-3b pStat3 fluorescence <br /> signaling pathways downstream S1P receptors. Spns2                  signals significantly reduced cells culture, <br /> expression led drastic reductions phospho-GSK-3b (pGSK-                Spns2 positive not, compared control GFP <br /> 3b, serine 9) A549 H1299 cells (Figs. 4A 4B). To             transfected cells (Con) (Figs. 4C 4D). This likely to <br /> validate observation, assayed GSK-3b&#226;&#8364;&#8482;s upstream activator            extracellular accumulation sphingolipids, Sph. More <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               6                        October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                     Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />                                                                                 Spns2 knockdown increases intracellular S1P level <br />                                                                                    The data demonstrate Spns2 regulates S1P <br />                                                                                 metabolism ectopic expression leads apoptosis in <br />                                                                                 NSCLC cells. To dissect Spns2&#226;&#8364;&#8482;s role LC, knocked <br />                                                                                 Spns2 siRNA. Figures 5A 5B siRNA <br />                                                                                 Spns2i-A significantly reduced Spns2 mRNA level than <br />                                                                                 80%. Thus used Spns2i-A studies. Scrambled <br />                                                                                 RNA (Scr) Spns2i-C (hereafter SpC), did suppress <br />                                                                                 Spns2 expression, used negative controls. <br />                                                                                    To characterize effect Spns2 knockdown sphingolipid <br />                                                                                 metabolism NSCLC cells, determined levels of <br />                                                                                 sphingolipid related enzymes. Lipidomics data <br />                                                                                 shows Spns2 knockdown Spns2i-A significantly increased <br />                                                                                 intracellular S1P level, reduced Sph level, A549 cells <br />                                                                                 compared Scr SpC (Figs. 5C S2A). The levels of <br />                                                                                 different ceramide species altered Spns2 knockdown <br />                                                                                 (Fig. S2B). This consistent previous report S1P <br />                                                                                 deficiency mice leads increased level S1P lung [33]. <br />                                                                                 In order analyze mechanism increased cellular S1P, we <br />                                                                                 measured levels major enzymes S1P metabolism. <br />                                                                                 Figure 5D shows levels multiple enzymes altered <br />                                                                                 Spns2 knockdown Spns2i-A: SGPP1 significantly <br />                                                                                 increased 8 fold; SGPP2 reduced ,50%; SGPL1 <br />                                                                                 reduced 80%. Increase SGPP1 accelerate <br />                                                                                 S1P conversion reduce cellular S1P level, be <br />                                                                                 counteracted reduction SGPP2 increase SGPL1. <br />                                                                                 However, SGPL1 abundantly expressed than <br />                                                                                 SGPP1 A549 cells (22 fold higher) (Fig. 5D). This explains why <br />                                                                                 S1P increased Spns2 knockdown. Other enzymes, such <br />                                                                                 SphKs, significantly affected Spns2 knockdown <br />                                                                                 (Figs. S2C S2D). <br />  <br />                                                                                 Spns2 knockdown enhances NSCLC cells migration <br />                                                                                    Functionally, examined Spns2 knockdown&#226;&#8364;&#8482;s role cell <br />                                                                                 survival/proliferation ectopic Spns2 expression induced <br />                                                                                 apoptosis. Live cell counting assays Spns2 knockdown <br />                                                                                 Spns2i-A did result significant increase number <br />                                                                                 viable cells A549 H1299 cells (not shown), indicating <br />                                                                                 Spns2 down-regulation does affect cell survival or <br />                                                                                 proliferation NSCLC cells. <br />                                                                                    We examined role Spns2 knockdown cell <br />                                                                                 migration intracellular S1P essential lung cell migration <br />                                                                                 motility [48]. Wound healing scratch assays performed <br />                                                                                 A549 cells H1299 cells. Four mm gaps <br /> Figure 4. Spns2 expression induces apoptosis down- <br /> regulating pro-survival pathways. (A), Western blot analyses                 generated confluent cultures micrographic images <br /> A549 cell samples. A549 Cells transiently transfected lysates          taken 8 24 hours post-scratching. Figure 6A shows typical <br /> collected 24 48 hours later blotted antibodies                 images assay A549 cells. Double blinded quantitative <br /> indicated. pGSK, phospho-GSK-3b; tGSK, total GSK-3b; pAkt, phospho-             analyses showed control A549 cells (Scr) migrated speed <br /> Akt; pStat3, phospho-Stat3; tStat3, total Stat3; Actin used            8.061.5 mm/h 5.460.8 mm/h 8 24 hour <br /> loading control. (B), Western blot analyses H1299 cell samples. <br />                                                                                 period, respectively (SpC cells similar result) (Fig. 6B). <br /> H1299 cells transiently transfected mentioned earlier. Cell <br /> lysates collected 48 hours later blotted antibodies           However, Spns2 knockdown cells migrated speed of <br /> indicated. (C), Confocal laser scan images cells stained pGSK-3b.        14.963.1 mm/h 10.060.3 mm/h time period, <br /> A549 cells transfected Spns2-GFP cover slips collected            representing 1.86 1.85 fold increase, respectively (Fig. 6B). <br /> after 48 hours. (D), Confocal laser scan images A549 cells stained       This observation replicated H1299 cells (Fig. 6C). To <br /> pStat3. Cells prepared C.                                            characterize phenomena specific LC cells, we <br /> doi:10.1371/journal.pone.0110119.g004 <br />                                                                                 transfected human primary brachial epithelial cells (HBEpC) with <br />                                                                                 Spns2i-A Spns2 knockdown did alter their <br /> interestingly, fluorescent signal pGSK-3b                   migration (not shown). <br /> reduced Spns2-GFP cells non-transfected cells (arrows                   To determine enhanced migration caused by <br /> Fig. 4C). These data confirm pro-survival pathways                   increased cellular S1P, inhibited S1P generation SphK <br /> were compromised Spns2 ectopically expressed.                          inhibitor, Ski-1. Figure 6D showed Ski-I treatment eradicated <br />                                                                                 enhanced migration mediated Spns2 knockdown, suggest- <br />                                                                                 ing cellular S1P major reason augmented migration <br />                                                                                 mediated Spns2 knockdown NSCLC cells. <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                  7                        October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                    Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />  <br /> Figure 5. Spns2 knockdown increases intracellular S1P level. (A), (B), Characterization Spns2 siRNAs. 20 nM Spns2 siRNA A, B, C <br /> were transfected individually A549 cells. 48 hours later total RNA collected RT-PCR (A) qRT-PCR (B) performed measure Spns2. <br /> Scrambled RNA (Scr) used negative control. (C), Spns2 knockdown Spns2i-A significantly increased intracellular S1P level. A549 Cells were <br /> transfected Spns2 siRNA A, 24 hours transfection, cell culture media changed media delipidated FBS. Another 24 hours <br /> later, cell pellets collected S1P analyzed lipidomics. N = 3. (D), Spns2 knockdown alters levels SGPP1, SGPP2, SGPL1. A549 Cells <br /> were treated A, qRT-PCR performed measure SGPP1, SGPP2, SGPL1. N = 4. qPCR data normalized GAPDH. <br /> doi:10.1371/journal.pone.0110119.g005 <br />  <br />    To determine cell signaling Spns2 knockdown-induced                 Discussion <br /> migration, measured Akt/PI3K Jak/Stat3 pathways. <br /> Spns2 knockdown Spns2i-A significantly increased levels                    Spns2 discovered zebrafish, spns2 <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-186' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-200' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-207' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span>mutation</span> <br /> pGSK-3b pStat3 compared controls (Fig. 6E),                   led migration defect myocardial precursors result, <br /> indicating PI3K/Akt Jak/Stat3 pathways activated                malformation heart [31,50]. Most recently, Spns2 found <br /> by Spns2 knockdown. To validate involvement                        essential lymphocyte trafficking mice [32,33,34]. <br /> pathways, supplemented LY294002 (an inhibitor PI3K)                     However remains unclear Spns2 plays role in <br /> and JAKi (an inhibitor Jak) media. Figure 6F shows           tumorigenesis cancer progression. Thus set test <br /> both inhibitors partially reversed migration mediated Spns2            Spns2&#226;&#8364;&#8482;s function cancer. LC chosen focus several <br />                                                                               reasons: 1) Spns2 abundantly expressed lung; 2) lung <br /> knockdown, confirming PI3K/Akt Jak/Stat3 pathways <br />                                                                               S1P level increased Spns2 <span id='am-238' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-239' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-240' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-245' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-249' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-251' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-252' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-256' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-259' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-260' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-262' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-263' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-265' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-267' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-270' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-272' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-273' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-287' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-292' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-295' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-298' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-300' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-303' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-304' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-312' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-314' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span>knockout</span> mice; 3) S1P <br /> play major roles migration mediated Spns2 knockdown. <br />                                                                               implicated early risk factor LC an <br /> These results consistent previous reports the <br />                                                                               epidemiology study [21,27,33]. <br /> PI3K/Akt JAK/Stat3 pathways crucial cell migration <br />                                                                                  Interestingly, functional studies demonstrate ectopic <br /> and motility [42,47,49]. <br />                                                                               Spns2 expression led apoptotic cell death NSCLC cells <br />                                                                               (Figs. 1 2). Although Spns2 transfection efficiency was <br /> Dysregulation Spns2 mRNA LC patient samples                             relatively low (,20%) (Figs. 1D, 1E, 4C 4D), mRNA levels of <br />   To build genetic link Spns2 human LC,                      S1PP1 S1P receptors S1P1-3 significantly reduced after <br /> determined Spns2 expression level deregulated                   Spns2 transfection (Fig. 3D 3E), protein levels <br /> patient samples. Real time quantitative PCR using small scale               pGSK-3b pStat3 (Fig. 4A). One possibility this <br /> qPCR array showed Spns2 mRNA levels significantly                   phenomenon enhanced secretion sphingolipids (such <br /> reduced stage 2B stage 3 samples compared                      Sph) overexpressing cells affected mRNA levels <br /> adjacent normal control tissues patients (Fig. 7).              pGSK-3b pStat3 protein levels none-transfected cells. <br /> Other stages did statistical significance, probably           Despite molecular changes, Spns2 transfected cells were <br /> small sample sizes. There stage 4 patient sample               apoptotic (Figs. 1D 1E), possibly caused an <br /> particular array. This data suggests Spns2 reduced             interplay intra- extra-cellular signals Spns2 <br /> the mRNA level advanced LC.                                                transfection. Furthermore, observed cytoskeletal changes <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                8                         October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                    Role Spns2 Lung Cancer Cells <br />  <br />  <br />  <br />  <br /> Figure 6. Spns2 knockdown enhances NSCLC cells migration. (A), Spns2 knockdown enhanced A549 cell migration. Representative images of <br /> the wound healing scratch assays. A549 cells transfected Spns2i-A. Scrambled RNA Spc used negative controls. 48 hours later, <br /> confluent cells treated mitomycin C, ,400 mm gap generated pipette tip. Micrographic images taken time points <br /> indicated. (B), Quantification A549 cell migration Spns2 knockdown. Average migration speed calculated using formula v = (G0&#226;&#8364;&#8220;Gt)/2t, in <br /> which v velocity speed; G0 gap size time 0, Gt gap size time t t time elapsed. N = 6. (C), Spns2 knockdown enhanced H1299 cell <br /> migration. H1299 cells treated A. Quantification B. N = 6. (D), SphK inhibition Ski-I eradicated enhanced migration of <br /> A549 cells mediated Spns2 knockdown. A549 cells treated A, cells treated SphK1 inhibitor Ski-I. Cell <br /> migration measured B. N = 6. *, p,0.05. (E), Spns2 knockdown increased pGSK-3b pStat3 levels. A549 cells treated earlier. Cells <br /> were collected western blot analysis performed detect proteins indicated. (F), Inhibition PI3K/Akt pathway LY 290004 (LY) and <br /> Jak/Stat3 pathway JAKi partially ameliorated Spns2 knockdown-mediated migration A549 cells. Cells treated migration quantified as <br /> mentioned earlier. N = 4. <br /> doi:10.1371/journal.pone.0110119.g006 <br />  <br /> after Spns2 transfection additional cause                  S1P metabolism regulated complex network enzymes <br /> apoptosis.                                                                    factors (Fig. 1A). In network, changes the <br />    Conversely, Spns2 knockdown siRNA led enhanced cell                  components shift equilibrium, including Spns2. Unsur- <br /> migration (Fig. 6). Inhibition S1P synthesis SphK inhibitor           prisingly, Spns2 expression dramatically increased extracellu- <br /> abolished Spns2 knockdown mediated cell migration (Fig. 6D),                  lar S1P level knockdown intracellular (Figs. 1C and <br /> suggesting cellular S1P major cause increased cell            3A), agrees previous reports [27,29,33,34]. Interest- <br /> migration Spns2 knockdown.                                              ingly, Spns2 transport sphingosine dihydro- <br />                                                                               sphingosine (Fig. 1C). However, cellular S1P level did <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                9                         October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                                      Role Spns2 Lung Cancer Cells <br />  <br />  <br />                                                                                          compared normal adjacent controls same <br />                                                                                          patients. This data suggest Spns2 potential risk <br />                                                                                          factor LC. <br />                                                                                             Taken together, demonstrated ectopic Spns2 <br />                                                                                          expression leads apoptosis knockdown results in <br />                                                                                          enhanced cell migration NSCLC cells. Interestingly, small <br />                                                                                          scale qPCR array analysis shows Spns2 mRNA level is <br />                                                                                          reduced advanced stage LC patients. These observations of <br />                                                                                          potential significance reducing apoptosis enhancing <br />                                                                                          migration complementary functions utilized cancer <br />                                                                                          cells progress aggressive forms. The characterization of <br />                                                                                          Spns2&#226;&#8364;&#8482;s function cancer expand understanding <br />                                                                                          S1P delivery function, contribute designing <br />                                                                                          new therapeutic strategies prevent treat LC. <br />  <br />                                                                                          Supporting Information <br /> Figure 7. Spns2 dysregulated LC patient samples. Real time <br /> quantitative PCR Spns2 LC samples. Norm, normal adjacent tissues                   Figure S1      (A), Intracellular ceramide profile A549 cells <br /> from patients; 2B, stage 2B; 3, stage 3. Spns2 levels                      Spns2 transfection. Cells changed media with <br /> normalized POLR2A levels. Sample sizes are: stage 2B: N = 8; stage 3:                 delipidated FBS 24 hours transfection. Another 24 hours <br /> N = 6. Error bars represent SD. *, p,0.05.                                               later, cell pellets collected, washed cold PBS 3 <br /> doi:10.1371/journal.pone.0110119.g007 <br />                                                                                          times, analyzed lipidomics. (B), Flow cytometry analysis of <br />                                                                                          Casp3 (FL2) positive cells Spns2-GFP control (GFP) cells. <br /> not change Spns2 expression (Fig. 3A), suggesting cells                       Data shown based GFP positive population. (C), The <br /> initiate compensatory mechanism make S1P loss                                pan caspase inhibitor ZVAD abolished Spns2 mediated cell death. <br /> mediated Spns2 expression. To delineate metabolic                                 (D), Ectopic Spns2 expression increased SphK2 protein level as <br /> mechanism, measured enzymes involved S1P metabo-                               shown western blot analysis. (E), Ectopic Spns2 expression <br /> lism. Our data indicated Spns2 expression led acute                              reduced SGPP1 SGPP2 expression shown RT-PCR. <br /> elevation SphK1 SphK2, enzymes generate S1P,                             (F), Ectopic Spns2 expression did alter SGPL1 expression as <br /> and reduction SGPP1, converts S1P (Figs. 3B&#226;&#8364;&#8220;3D, S1D).                           shown qPCR. <br /> On hand, cells Spns2 knocked-down <br />                                                                                          (PDF) <br /> increased S1P conversion dramatically increasing SGPP1 <br /> (Fig. 5D). However, levels SGPP2 abundantly                          Figure S2 (A), Intracellular Sph reduced Spns2 <br /> expressed SGPL1 greatly reduced (Fig. 5D). This                          knockdown A549 cells. (B), Intracellular ceramide altered <br /> of main reasons intracellular S1P level increased                      significantly Spns2 knockdown. (C) (D), Spns2 knockdown <br /> Spns2 knockdown.                                                                         did alter significantly expression SphK1 SphK2. <br />    To understand increased extracellular S1P (caused                              (PDF) <br /> Spns2 expression) did protective effect, measured <br /> the levels S1P receptors S1P1-S1P3                       Acknowledgments <br /> significantly down-regulated Spns2 expression (Fig. 3E). <br /> Furthermore, Spns2 expression down-regulated, Spns2                                We thank Dr. John Cowell invaluable scientific input. We thank Dr. <br />                                                                                          Zhonglin Hao Ms. Mei Hong providing NSCLC cell lines. We <br /> knockdown activated, Akt/PI3K Jak/Stat3 pathways <br />                                                                                          thank Ms. Haiyan Qin technical support. <br /> (Figs. 4 6E). Inhibition pathways partially abolished <br /> the enhanced migration, validating PI3K/Akt Jak/ <br /> Stat3 signaling directly involved Spns2 knockdown                                 Author Contributions <br /> mediated migration (Fig. 6F). This consistent previous                           Conceived designed experiments: E. Bieberich GW. Performed the <br /> publications pathways vital cell migration                    experiments: E. Bradley SD XZ GZ QH MD GW. Analyzed data: E. <br /> [47,49].                                                                                 Bradley XJ E. Bieberich GW. Contributed reagents/materials/analysis <br />    In line vitro studies, Spns2 mRNA                         tools: XJ. Contributed writing manuscript: E. Bradley SD MD <br /> down-regulated advanced stage LC patient samples (Fig. 7)                             E. Bieberich GW. <br />  <br />  <br /> References <br />  1. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:               7. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA (2001) DNA methyltrans- <br />     1367&#226;&#8364;&#8220;1380.                                                                               ferase inhibition enhances apoptosis induced histone deacetylase inhibitors. <br />  2. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, et al. (2012) A novel              Cancer Res 61: 1327&#226;&#8364;&#8220;1333. <br />     classification lung cancer molecular subtypes. PLoS One 7: e31906.            8. Shinjo K, Kondo Y (2012) Clinical implications epigenetic alterations in <br />  3. American-Cancer-Society (2012) Cancer Facts &amp; Figures 2012. Atlanta.                     human thoracic malignancies: epigenetic alterations lung cancer. Methods <br />  4. Heist RS, Sequist LV, Engelman JA (2012) Genetic changes squamous cell                Mol Biol 863: 221&#226;&#8364;&#8220;239. <br />     lung cancer: review. J Thorac Oncol 7: 924&#226;&#8364;&#8220;933.                                     9. Nakata A, Gotoh N (2012) Recent understanding molecular mechanisms <br />  5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005)             efficacy resistance EGF receptor-specific tyrosine kinase inhibitors <br />     Erlotinib previously treated non-small-cell lung cancer. N Engl J Med 353:            non-small cell lung cancer. Expert Opin Ther Targets 16: 771&#226;&#8364;&#8220;781. <br />     123&#226;&#8364;&#8220;132.                                                                             10. Huang YL, Huang WP, Lee H (2011) Roles sphingosine 1-phosphate on <br />  6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010)                          tumorigenesis. World J Biol Chem 2: 25&#226;&#8364;&#8220;34. <br />     Anaplastic lymphoma kinase inhibition non-small-cell lung cancer.                 11. Spiegel S, Milstien S (2011) The outs ins sphingosine-1-phosphate in <br />     N Engl J Med 363: 1693&#226;&#8364;&#8220;1703.                                                             immunity. Nat Rev Immunol 11: 403&#226;&#8364;&#8220;415. <br />  <br />  <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                          10                             October 2014 | Volume 9 | Issue 10 | e110119 <br />                                                                                                                                         Role Spns2 Lung Cancer Cells <br />  <br />  <br /> 12. Spiegel S, Cuvillier O, Edsall L, Kohama T, Menzeleev R, et al. (1998) Roles         32. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, et al. (2012) The <br />     sphingosine-1-phosphate cell growth, differentiation, death. Biochemistry            sphingosine-1-phosphate transporter Spns2 expressed endothelial cells <br />     (Mosc) 63: 69&#226;&#8364;&#8220;73.                                                                           regulates lymphocyte trafficking mice. J Clin Invest 122: 1416&#226;&#8364;&#8220;1426. <br /> 13. Chalfant CE, Spiegel S (2005) Sphingosine 1-phosphate ceramide 1-                   33. Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, et al. (2012) <br />     phosphate: expanding roles cell signaling. J Cell Sci 118: 4605&#226;&#8364;&#8220;4612.                    Spns2, transporter phosphorylated sphingoid bases, regulates blood <br /> 14. Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, et al. (2011) Tumor-                       lymph levels lymphatic network. FASEB J. <br />     suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting            34. Mendoza A, Breart B, Ramos-Perez WD, Pitt LA, Gobert M, et al. (2012) The <br />     sphingosine-1-phosphate receptor-1 sphingosine kinase 1 - Jekyll Hidden                 transporter spns2 required secretion lymph plasma sphingosine- <br />     Hyde. Am J Cancer Res 1: 460&#226;&#8364;&#8220;481.                                                    1-phosphate. Cell Rep 2: 1104&#226;&#8364;&#8220;1110. <br /> 15. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, et al.                     35. Wang G, Krishnamurthy K, Tangpisuthipongsa D (2011) Protection murine <br />     (2012) Sphingosine-1-phosphate produced sphingosine kinase 1 promotes                    neural progenitor cells Hsp90 inhibitor 17-allylamino-17-demethoxygel- <br />     breast cancer progression stimulating angiogenesis lymphangiogenesis.                danamycin low nanomolar concentration range. J Neurochem 117: 703&#226;&#8364;&#8220; <br />     Cancer Res 72: 726&#226;&#8364;&#8220;735.                                                                     711. <br /> 16. Cuvillier O (2008) Downregulating sphingosine kinase-1 cancer therapy.              36. Bradley E, Bieberich E, Mivechi NF, Tangpisuthipongsa D, Wang G (2012) <br />     Expert Opin Ther Targets 12: 1009&#226;&#8364;&#8220;1020.                                                     Regulation embryonic stem cell pluripotency heat shock protein 90. Stem <br /> 17. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, et al. (2012) First                Cells 30: 1624&#226;&#8364;&#8220;1633. <br />     evidence sphingosine 1-phosphate lyase protein expression activity               37. Wang G, Dinkins M, He Q, Zhu G, Poirier C, et al. (2012) Astrocytes secrete <br />     downregulation human neoplasm: implication resistance therapeutics             exosomes enriched proapoptotic ceramide prostate apoptosis response <br />     prostate cancer. Mol Cancer Ther 11: 1841&#226;&#8364;&#8220;1851.                                             4 (PAR-4): potential mechanism apoptosis induction Alzheimer disease <br /> 18. Hisano Y, Nishi T, Kawahara A (2012) The functional roles S1P immunity.               (AD). J Biol Chem 287: 21384&#226;&#8364;&#8220;21395. <br />     J Biochem 152: 305&#226;&#8364;&#8220;311.                                                                 38. Wang G, Krishnamurthy K, Umapathy NS, Verin AD, Bieberich E (2009) The <br /> 19. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI (2007)                           carboxyl-terminal domain atypical protein kinase Czeta binds ceramide <br />     Activation sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte                regulates junction formation epithelial cells. J Biol Chem 284: 14469&#226;&#8364;&#8220; <br />     progenitor migration. FASEB J 21: 1503&#226;&#8364;&#8220;1514.                                                14475. <br /> 20. Maceyka M, Harikumar KB, Milstien S, Spiegel S (2012) Sphingosine-1-                    39. Wang G, Ying Z, Jin X, Tu N, Zhang Y, et al. (2004) Essential requirement for <br />     phosphate signaling role disease. Trends Cell Biol 22: 50&#226;&#8364;&#8220;60.                    hsf1 hsf2 transcriptional activity spermatogenesis male fertility. <br /> 21. Alberg AJ, Armeson KE, Pierce JS, Bielawski J, Bielawska A, et al. (2013) Plasma            Genesis 38: 66&#226;&#8364;&#8220;80. <br />     sphingolipids markers future lung cancer risk: A population-based, nested         40. Wang G, Silva J, Dasgupta S, Bieberich E (2008) Long-chain ceramide is <br />     case-control study. Cancer Epidemiol Biomarkers Prev.            <br /> </body></html>